ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

This study is testing a combination of stem cell transplant (ASCT), BCMA-targeting CAR-T cell therapy, and a maintenance drug (GPRC5D/CD3 BiTE) for newly diagnosed multiple myeloma patients who have very high-risk disease features. **You may be eligible if:** - You are between 18 and 70 years old - You have newly diagnosed multiple myeloma with measurable disease - You have at least one ultra-high-risk feature such as certain genetic abnormalities (like TP53 mutation, deletion of chromosome 17p, or multiple cytogenetic abnormalities) - You are fit enough to undergo a stem cell transplant - Your liver and kidney function are adequate **You may NOT be eligible if:** - You have already received treatment for multiple myeloma - You are not medically eligible for a stem cell transplant - Your organ function does not meet requirements Talk to your doctor to see if this trial is right for you.